Novozymes Biopharma has initiated the first shipment of its Bacillus-derived hyaluronic acid, Hyasis, from its new manufacturing facility in China. The first commercial products using Hyasis as a raw material are expected to reach the market in 2Q12.
“Shipment of the first commercial hyaluronic acid material from our new Q7 GMP facility marks an important milestone on our journey to becoming a leading producer of high quality hyaluronic acid. With our new patented process, based on the safe bacteria Bacillus subtilis, the market will have access to a new improved source of HA which is fully compliant with the highest pharmaceutical standards and developed with customers’ specific needs in mind,” said Thomas Videbæk, executive vice president of Novozymes A/S.
Hyasis has been specifically designed to fill a gap in the market for biomedical and pharmaceutical manufacturers looking for Q7 regulatory compliant ingredients with enhanced performance benefits. The Tianjin, China facility was designed exclusively for Hyasis and employs a patented water-based process to manufacture Hyasis to Q7 cGMP standards.
“Improving how our customers can process and formulate HA for medical applications has been the key driver in the development of Novozymes’ new patented HA production process and facility,” said Hans Ole Klingenberg, global marketing director at Novozymes. “Our unique technology will expand opportunities in the pharmaceutical and biomedical industries across multiple applications for HA, creating improved therapeutic treatments with real benefits for both manufacturers and patients.”